Ocugen (OCGN) Stock Price, News & Analysis

Company Overview

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Key Stats

• Today's Range: $0.97 to $1.01
• 50-Day Range: $0.84 to $1.20
• 52-Week Range: $0.52 to $1.40
• Volume: 2.36 million shs
• Average Volume: 3.17 million shs
• Market Capitalization: $291.83 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Buy

Ocugen Stock Analysis - MarketRank™

Ocugen scored higher than 32% of companies evaluated by MarketBeat, and ranked 773rd out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Ocugen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Ocugen has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Ocugen are expected to decrease in the coming year, from ($0.20) to ($0.26) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ocugen is -4.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ocugen is -4.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ocugen has a P/B Ratio of 99.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.20% of the outstanding shares of Ocugen have been sold short.

Short Interest Ratio / Days to Cover

Ocugen has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Ocugen has recently decreased by 11.20%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ocugen does not currently pay a dividend.

Dividend Growth

Ocugen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

19.20% of the outstanding shares of Ocugen have been sold short.

Short Interest Ratio / Days to Cover

Ocugen has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Ocugen has recently decreased by 11.20%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.70

News Sentiment

Ocugen has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Ocugen this week, compared to 4 articles on an average week.

Search Interest

Only 8 people have searched for OCGN on MarketBeat in the last 30 days. This is a decrease of -47% compared to the previous 30 days.

MarketBeat Follows

Only 6 people have added Ocugen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ocugen insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.42% of the stock of Ocugen is held by insiders.

Percentage Held by Institutions

Only 10.27% of the stock of Ocugen is held by institutions.

OCGN Stock Analysis - Frequently Asked Questions

How have OCGN shares performed this year?

Ocugen's stock was trading at $0.8050 at the beginning of the year. Since then, OCGN shares have increased by 24.0% and is now trading at $0.9984.

How were Ocugen's earnings last quarter?

Ocugen, Inc. (NASDAQ:OCGN) issued its quarterly earnings results on Friday, August, 1st. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. The business had revenue of $1.37 million for the quarter, compared to the consensus estimate of $0.35 million. Ocugen had a negative net margin of 1,197.71% and a negative trailing twelve-month return on equity of 255.25%.
Read the conference call transcript.

Who are Ocugen's major shareholders?

Ocugen's top institutional investors include Geode Capital Management LLC (1.19%), Y Intercept Hong Kong Ltd (0.12%), Procyon Advisors LLC (0.07%) and Creative Planning (0.02%). Insiders that own company stock include Shankar Musunuri, Junge Zhang, Kirsten Castillo, Prabhavathi Fernandes and Ramesh Kumar.
View institutional ownership trends.

How do I buy shares of Ocugen?

Shares of OCGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ocugen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ocugen investors own include Zomedica (ZOM), American Water Works (AWK), Waste Connections (WCN), AU Optronics (AUOTY), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and The RMR Group (RMR).

Company Calendar

• Last Earnings: 8/01/2025
• Today: 8/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OCGN
• CIK: 1372299
• Web: ocugen.com
• Phone: (484) 328-4701
• Fax: 781-547-4452
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Ocugen: $6.00
• High Price Target: $7.00
• Low Price Target: $4.00
• Potential Upside/Downside: +501.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$54.05 million
• Net Margins: -1,197.71%
• Pretax Margin: -1,197.71%
• Return on Equity: -255.25%
• Return on Assets: -86.79%

Debt

• Debt-to-Equity Ratio: 9.18
• Current Ratio: 1.83
• Quick Ratio: 2.60

Sales & Book Value

• Annual Sales: $4.05 million
• Price / Sales: 72.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.01 per share
• Price / Book: 99.84

Miscellaneous

• Outstanding Shares: 292,300,000
• Free Float: 279,385,000
• Market Cap: $291.83 million
• Optionable: Optionable
• Beta: 3.84